Inhibikase Therapeutics reported a significant increase in total assets to $201.8 million as of September 30, 2026, driven by a substantial rise in marketable securities. The company's accumulated deficit grew to $199.1 million, reflecting ongoing research and development investments, while common stock outstanding increased to 140,269,633 shares.
Inhibikase Therapeutics reported financial results for the third quarter of 2026, highlighting the expansion of its Phase 3 IMPROVE-PAH study for IKT-001 with 28 country regulatory approvals and 79 clinical sites activated. The company noted it is well-capitalized following a $50 million equity sale to RA Capital in July 2026, which will support the advancement of its PAH clinical program.
Term
Q3 2026
“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries.”
Mark Iwicki, Chief Executive Officer of Inhibikase
“Supported by the $50 million proceeds from the sale of shares to RA Capital in July, Inhibikase is well-positioned to advance IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”
Mark Iwicki, Chief Executive Officer of Inhibikase
Inhibikase Therapeutics appointed Dr. Scott Wasserman to its Board of Directors and the Compensation Committee, effective October 19, 2026. Dr. Wasserman, currently CMO of Kailera Therapeutics and a former Amgen executive, succeeds Dennis Berman, who resigned from the Board on the same date. The change occurs as the company advances its Phase 3 IMPROVE-PAH study of IKT-001.